Прогресс в лечении псориатического артрита


Т.В. Коротаева

ФГБНУ НИИР им. В. А. Насоновой РАМН, Москва
В последние годы терапия псориатического артрита ( ПсА) претерпела значительные изменения, что связано в первую очередь с открытием ряда цитокинов, участвующих в иммунопатогенезе заболевания, в первую очередь фактора некроза опухоли α, интерлейкинов 12, 23, 17 и др. В статье проведен анализ перспективных направлений терапии ПсА. Развитие биологической терапии в настоящее время рассматривают как существенный прорыв в разработке новых подходов к лечению ПсА.

Литература


  1. Smolen J.S., Braun J., Dougados M., Emery P., Fitzgerald O., Helliwell P., Kavanaugh A., Kvien T.K., Landewe R., Luger T., Mease P., Olivieri I., Reveille J., Ritchlin C., Rudwaleit M., Schoels M., Sieper J., Wit Md., Baraliakos X., Betteridge N., Burgos-Vargas R., Collantes-Estevez E., Deodhar A., Elewaut D., Gossec L., Jongkees M., Maccarone M., Redlich K., van den Bosch F., Wei J.C., Winthrop K., van der Heijde D. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann. Rheum. Dis. 2014;73:6–16.
  2. Sherlock J.P., Joyce-Shaikh B., Turner S.P., Chao C.C., Sathe M., Grein J., Gorman D.M., Bowman E.P., McClanahan T.K., Yearley J.H., Eberl G., Buckley C.D., Kastelein R.A., Pierce R.H., Laface D.M., Cua D.J. IL-23 induces spondyloarthropathy by acting on RORct+CD3+CD4-CD8- entheseal resident T cells. Nat. Med. 2012;18:1069–76.
  3. Cortesi P.A., Scalone L., D’Angiolella L., Belisari A., Fusco F., Olivieri I., Mantovani L.G. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin. Exp. Rheumatol. 2012;30:126–31.
  4. Fagerli K.M., Lie E., van der Heijde D., Lexberg A.S., Rоdevand E., Kalstad S., Mikkelsen K., Kvien T.K. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann. Rheum. Dis. 2014;73(1):132–37.
  5. Коротаева Т.В., Логинова Е.Ю., Каратеев Д.Е. и др. Стратегия «Лечение до достижения цели» при раннем псориатическом артрите (предварительные результаты исследования РЕМАРКА). Научно-практическая рев-матология. 2014;52(4):376–80.
  6. Красненко С.О., Логинова Е.Ю., Коротаева Т.В., Смирнов А.В. Сравнительная характеристика данных МРТ, рентгенологического и клинического исследования кистей и стоп у больных с ранним ПсА. Научно-практическая ревматология. 2013;2:149–53.
  7. Navarro-Sarabia F., Ariza-Ariza R., Hernandez-Cruz B., Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst. Rev. 2005:CD005113.
  8. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., Sharp J.T., Ory P.A., Perdok R.J., Weinberg M.A.; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebocontrolled trial. Arthritis Rheum. 2005;52:3279–89.
  9. Kavanaugh A., McInnes I., Mease P., Krueger G.G., Gladman D., Gomez-Reino J., Papp K., Zrubek J., Mudivarthy S., Mack M., Visvanathan S., Beutler A. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–86.
  10. Saber T.P., Veale D.J. Psoriatic arthritis management update–biotherapeutic options. J. Rheumatol. Suppl. 2009;83:65–8.
  11. Glintborg B., Ostergaard M., Dreyer L., Krogh N.S., Tarp U., Hansen M.S., Rifbjerg-Madsen S., Lorenzen T., Hetland M.L. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63:382–90.
  12. Saad A.A., Symmons D.P., Noyce P.R., Ashcroft D.M. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J. Rheumatol. 2008;35:883–90.
  13. NICE technology appraisal guidance 199. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. www.nice.org.uk.
  14. Russolillo A., Iervolino S., Peluso R., Lupoli R., Di Minno A., Pappone N., Di Minno M.N. Obesity and psoriatic arthritits: from pathogenesis to clinical outcome and management. Rheumatology (Oxford). 2012;1(52):62–7.
  15. Thorlund K., Druyts E., Avina-Zubieta J.A., Mills E.J. Antitumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison metaanalysis. Biologics. 2012;6:417–27.
  16. McGonagle D., Wakefield R.J., Tan A.L., D’Agostino M.A., Toumi H., Hayashi K., Emery P., Benjamin M. Distinct topography of erosion and new bone formation in achilles tendon enthesitis: implications for understanding the link between inflammation and bone formation in spondylarthritis. Arthritis Rheum. 2008;58:2694–99.
  17. Sterry W., Ortonne J.P., Kirkham B., Brocq O., Robertson D., Pedersen R.D., Estojak J., Molta C.T., Freundlich B. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double blind multicentre trial. BMJ. 2010;340:147.
  18. Gottl.ieb A., Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther. Adv. Musculoskel. Dis. 2013;5:277–85.
  19. FitzGerald O., Helliwell P., Mease P., Mumtaz A., Coates L., Pedersen R., Nab H., Molta C. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. An. Rheum. Dis. 2012;71:358–62.
  20. Mease P.J., Ory P., Sharp J.T., Ritchlin C.T., Van den Bosch F., Wellborne F., Birbara C., Thom-son G.T., Perdok R.J., Medich J., Wong R.L., Gladman D.D. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis. 2009;68:702–9.
  21. Ritchlin C.T. Therapeutic considerations in spondyloarthritis patients who fail tumour necrosis factor antagonists. Best Pract. Res. Clin. Rheumatol. 2010;24:683–92.
  22. Gottlieb A., Menter A., Mendelsohn A., Shen Y.K., Li S., Guzzo C., Fretzin S., Kunynetz R., Kavanaugh A. Ustekinumab, a human interleukin 12/2 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–40.
  23. Heiberg M.S., Koldingsnes W., Mikkelsen K., Rоdevand E., Kaufmann C., Mowinckel P., Kvien T.K. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis. Biol. Ther. 2013;3:61–81.
  24. Rodgers M., Epstein D., Bojke L., Yang H., Craig D., Fonseca T., Myers L., Bruce I., Chalmers R., Bujkiewicz S., Lai M., Cooper N., Abrams K., Spiegelhalter D., Sutton A., Sculpher M., Woolacott N. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol. Assess. 2011;15:1–329.
  25. Goulabchand R., Mouterde G., Barnetche T., Lukas C., Morel J., Combe B. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 2014;73(2):414–19.
  26. Cargill M., Schrodi S.J., Chang M., Garcia V.E., Brandon R., Callis K.P., Matsunami N., Ardlie K.G., Civello D., Catanese J.J., Leong D.U., Panko J.M., McAllister L.B., Hansen C.B., Papenfuss J., Prescott S.M., White T.J., Leppert M.F., Krueger G.G., Begovich A.B. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 2007;80:273–90.
  27. Yeilding N., Szapary P., Brodmerkel C., Benson J., Plotnick M,. Zhou H., Goyal K., Schenkel B., Giles-Komar J., Mascelli M.A., Guzzo C. Development of IL-12/23 antagonist ustekinumab: past, present and future perspectives. Ann. NY. Acad. Sci. 2011;1222:30–9.
  28. Wada Y., Lu R., Zhou D., Chu J., Przewloka T., Zhang S., Li L., Wu Y., Qin J., Balasubramanyam V., Barsoum J., Ono M. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007;109:1156–64.
  29. Krausz S., Boumans M.J., Gerlag D.M., Lufkin J., van Kuijk A.W., Bakker A., de Boer M., Lodde B.M., Reedquist K.A., Jacobson E.W., O’Meara M., Tak P.P. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:1750–55.
  30. Johansen C., Usher P.A., Kjellerup R.B., Lundsgaard D., Iversen L., Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br. J. Dermatol. 2009;160:319–24.
  31. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., Antoni C., Draelos Z., Gold M.H. Psoriasis Study Group, Durez P., Tak P.P., Gomez-Reino J.J.; Rheumatoid Arthritis Study Group, Foster C.S., Kim R.Y., Samson C.M., Falk N.S., Chu D.S., Callanan D., Nguyen Q.D.; Uveitis Study Group, Rose K., Haider A., Di Padova F. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2010;2:52–72.
  32. McInnes I.B., Sieper J., Braun J., Emery P., van der Heijde D., Isaacs J.D., Dahmen G., Wollenhaupt J., Schulze-Koops H., Kogan J., Ma S., Schumacher M.M., Bertolino A.P., Hueber W., Tak P.P. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. 32. Ann. Rheum. Dis. 2014;73(2):349–56.
  33. Krueger G., Gottlieb A., Sterry W. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J. Dermatol. Treat. 2008;19:146–55.
  34. Ellis C.N., Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. NEJM. 2001;345:248–55.
  35. Brimhall A.K., King L.N., Licciardone J.C., Jacobe H., Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br. J. Dermatol. 2008;159:274–85.
  36. Mease P., Genovese M.C., Gladstein G., Kivitz A.J., Ritchlin C., Tak P.P., Wollenhaupt J., Bahary O., Becker J.C., Kelly S., Sigal L., Teng J., Gladman D. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebocontrolled, phase II trial. Arthritis Rheum. 2011;63:939–48.
  37. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S., Menter A., Lowe N.J., Krueger G., Brown M.J., Weiner R.S., Birkhofer M.J., Warner G.L., Berry K.K., Linsley P.S., Krueger J.G., Ochs H.D., Kelley S.L., Kang S. TLA4 Ig mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 1999;103:1243–52.
  38. Canete J.D., Celis R., Hernandez V., Pablos J.L., Sanmarti R. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann. Rheum. Dis. 2010;69:935–36.
  39. Wagner J., von Matt P., Faller B., Cooke N.G., Albert R., Sedrani R., Wiegand H., Jean C., Beerli C., Weckbecker G., Evenou J.P., Zenke G., Cottens S. Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis. J. Med. Chem. 2011;54:6028–39.
  40. Boy M.G., Wang C., Wilkinson B.E., Chow V.F., Clucas A.T., Krueger J.G., Gaweco A.S., Zwillich S.H., Changelian P.S., Chan G. Double blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J. Invest. Dermatol. 2009;129:2299–302.
  41. Schett G., Wollenhaupt J., Papp K., Joos R., Rodrigues J.F., Vessey A.R., Hu C., Stevens R., de Vlam K.L. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156–67.
  42. Mease P.J., Wei N., Fudman E.J., Kivitz A.J., Schechtman J., Trapp R.G., Hobbs K.F., Greenwald M., Hou A., Bookbinder S.A., Graham G.E., Wiesenhutter C.W., Willis L., Ruderman E.M., Forstot J.Z., Maricic M.J., Dao K.H., Pritchard C.H., Fiske D.N., Burch F.X., Prupas H.M., Anklesaria P., Heald A.E. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adenoassociated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J. Rheumatol. 2010;37:692–703.
  43. Schnepp B.C., Jensen R.L., Chen C.L., Johnson P.R., Clark K.R. Characterization of adeno-associated virus genomes isolated from human tissues. J. Virol. 2005;79:14793–803.
  44. Mease P.J., Hobbs K., Chalmers A., El-Gabalawy H., Bookman A., Keystone E., Furst D.E., Anklesaria P., Heald A.E. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Ann. Rheum. Dis. 2009;68:1247–54.


Об авторах / Для корреспонденции


Т.В. Коротаева – ФГБНУ НИИР им. В. А. Насоновой РАМН, Москва


Похожие статьи


Бионика Медиа